Staphylococcal Protein A Induces Leukocyte Necrosis by Complexing with Human Immunoglobulins.


Journal

mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231

Informations de publication

Date de publication:
29 06 2021
Historique:
pubmed: 2 6 2021
medline: 16 11 2021
entrez: 1 6 2021
Statut: ppublish

Résumé

One of the defining features of Staphylococcus aureus is its ability to evade and impair the human immune response through expression of staphylococcal protein A (SpA). Herein, we describe a previously unknown mechanism by which SpA can form toxic immune complexes when in the presence of human serum, which leads to the loss of human leukocytes. Further, we demonstrate that these toxic complexes are formed specifically through SpA's interaction with intact human IgG and that, in the presence of purified IgG Fab and Fc fragments, SpA shows no such toxicity. The mechanism of action of this toxicity appears to be one mediated by necrosis and not by apoptosis, as previously hypothesized, with up to 90% of human B cells rapidly becoming necrotic following stimulation with SpA-IgG complexes. This phenomenon depends on the immunoglobulin binding capacity of SpA, as a nonbinding mutant of SpA did not induce necrosis. Importantly, immune sera raised against SpA had the capacity to significantly reduce the observed toxicity. An unprecedented toxic effect of SpA-IgG complexes on monocytes was also observed, suggesting the existence of a novel mechanism independent from the interaction of SpA with the B cell receptor. Together, these data implicate SpA in inducing indiscriminate leukocyte toxicity upon formation of complexes with IgG and highlight the requirement for vaccination strategies to inhibit this mechanism.

Identifiants

pubmed: 34060329
doi: 10.1128/mBio.00899-21
pmc: PMC8262926
doi:

Substances chimiques

Antigen-Antibody Complex 0
Immunoglobulin G 0
Staphylococcal Protein A 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0089921

Références

FEMS Microbiol Rev. 2015 Sep;39(5):750-63
pubmed: 25994610
J Clin Pharmacol. 2013 Sep;53(9):909-18
pubmed: 23832863
Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1574-9
pubmed: 24434550
Haematologica. 2006 Jan;91(1):40-7
pubmed: 16434369
J Immunol. 2017 Feb 1;198(3):1263-1273
pubmed: 28031339
Proc Natl Acad Sci U S A. 2016 May 17;113(20):5718-23
pubmed: 27140614
Nat Rev Immunol. 2006 Jun;6(6):465-75
pubmed: 16724100
Structure. 2014 Oct 7;22(10):1467-77
pubmed: 25295398
Front Immunol. 2018 Sep 19;9:2011
pubmed: 30283436
mBio. 2013 Aug 27;4(5):e00575-13
pubmed: 23982075
J Immunol. 2006 Feb 15;176(4):2262-71
pubmed: 16455982
Cancer Cell Int. 2014 Nov 26;14(1):114
pubmed: 25493072
BMJ. 2013 Mar 11;346:f1493
pubmed: 23479660
Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):448-55
pubmed: 24674306
Mol Immunol. 2008 Mar;45(6):1600-11
pubmed: 18061675
Curr Top Microbiol Immunol. 2017;409:491-528
pubmed: 28197738
Infect Immun. 1977 Mar;15(3):760-4
pubmed: 870431
mBio. 2013 Oct 01;4(5):e00764-13
pubmed: 24085782
Clin Pharmacol Drug Dev. 2014 Nov;3(6):477-86
pubmed: 27129122
Curr Top Microbiol Immunol. 2017;409:21-56
pubmed: 27025380
J Immunol. 1998 Jun 1;160(11):5246-52
pubmed: 9605120
Front Microbiol. 2019 May 10;10:863
pubmed: 31133995
J Immunol. 2007 Mar 1;178(5):2803-12
pubmed: 17312124
mBio. 2015 Jan 06;6(1):
pubmed: 25564466
J Immunol. 2008 Jan 1;180(1):361-71
pubmed: 18097037
J Infect Dis. 2019 Feb 23;219(6):884-888
pubmed: 30551184
Front Cell Infect Microbiol. 2012 Feb 22;2:16
pubmed: 22919608
Curr Top Microbiol Immunol. 2017;409:419-439
pubmed: 26919865
Clin Microbiol Rev. 2012 Apr;25(2):362-86
pubmed: 22491776
Infect Immun. 2006 Feb;74(2):1196-203
pubmed: 16428769
Eur J Biochem. 1986 May 2;156(3):637-43
pubmed: 2938951
J Exp Med. 2014 Nov 17;211(12):2331-9
pubmed: 25348152
J Bacteriol. 2018 Apr 9;200(9):
pubmed: 29440258
J Exp Med. 1993 Jul 1;178(1):331-6
pubmed: 8315388
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5399-404
pubmed: 10805799
J Immunol. 1998 Aug 1;161(3):1204-11
pubmed: 9686580
J Exp Med. 2010 Aug 30;207(9):1863-70
pubmed: 20713595
Infect Immun. 2012 Oct;80(10):3460-70
pubmed: 22825452
EMBO J. 2007 Feb 7;26(3):701-9
pubmed: 17255933
Nat Med. 2004 Aug;10(8):842-8
pubmed: 15247912
mBio. 2018 Mar 13;9(2):
pubmed: 29535203
Vaccine. 2016 Apr 4;34(15):1792-9
pubmed: 26921780

Auteurs

Proinnsias G Fox (PG)

GSK, Siena, Italy.
Host-Pathogen Interactions Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.

Francesca Schiavetti (F)

GSK, Siena, Italy.

Rino Rappuoli (R)

GSK, Siena, Italy.

Rachel M McLoughlin (RM)

Host-Pathogen Interactions Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.

Fabio Bagnoli (F)

GSK, Siena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH